Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) EBIT (2017 - 2025)

Historic EBIT for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to -$71.6 million.

  • Autolus Therapeutics' EBIT fell 551.74% to -$71.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$273.9 million, marking a year-over-year decrease of 2518.31%. This contributed to the annual value of -$241.4 million for FY2024, which is 3434.87% down from last year.
  • As of Q3 2025, Autolus Therapeutics' EBIT stood at -$71.6 million, which was down 551.74% from -$61.2 million recorded in Q2 2025.
  • Autolus Therapeutics' EBIT's 5-year high stood at -$40355.0 during Q3 2021, with a 5-year trough of -$75.9 million in Q4 2024.
  • In the last 5 years, Autolus Therapeutics' EBIT had a median value of -$39.9 million in 2021 and averaged -$44.4 million.
  • Its EBIT has fluctuated over the past 5 years, first surged by 9990.55% in 2021, then plummeted by 9244615.29% in 2022.
  • Quarter analysis of 5 years shows Autolus Therapeutics' EBIT stood at -$23.1 million in 2021, then skyrocketed by 49.57% to -$11.6 million in 2022, then crashed by 357.26% to -$53.3 million in 2023, then crashed by 42.41% to -$75.9 million in 2024, then rose by 5.59% to -$71.6 million in 2025.
  • Its last three reported values are -$71.6 million in Q3 2025, -$61.2 million for Q2 2025, and -$65.2 million during Q1 2025.